Stocks
Hemab Therapeutics Holdings, Inc.COAG
NASDAQHealthcareBiotechnology$34.63
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing novel therapies for rare bleeding and thrombotic disorders, with a focus on hemophilia and related conditions. Its lead programs target unmet needs in hemostasis, and investors track the company for its potential to address significant market gaps in rare disease treatment.
52W Range: $23.00-$55.42
Congressional Interest in Hemab Therapeutics Holdings, Inc. (COAG)
No congressional trades have been disclosed for Hemab Therapeutics Holdings, Inc. (COAG) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading COAG?
No congressional trades found for this stock.